NAD+ vs. MOTS-C: The Longevity Compound Group, Compared

For research and educational purposes only. Nothing in this guide constitutes medical advice. Consult a qualified healthcare professional before beginning any new protocol. Neither compound discussed here is approved by Health Canada or the FDA for the research applications described.

Last updated: July 2026

---

NAD+ and MOTS-C get grouped together for a reason that has nothing to do with how they actually work: both are pitched as ways to restore something the body simply makes less of as it ages. Beyond that shared framing, they’re genuinely different tools — different molecule types, different mechanisms, different evidence problems. This guide puts them side by side so you can see exactly where they overlap and where they don’t.

At a Glance

	NAD+	MOTS-C
Type	Coenzyme (not a peptide)	Mitochondrial-derived peptide
Discovered / first used	First clinical use described 1961 (unrelated indication)	Discovered 2015, USC
Mechanism	Electron carrier for ATP production; substrate for sirtuins and PARP DNA-repair enzymes	AMPK activation — cellular energy sensing, glucose uptake, fat oxidation
Rationale	Levels decline ~40–50% between young adulthood and middle age	Levels decline with age and are lower in metabolic disease
Completed injectable human outcomes trials	None found in a 2025 systematic review	None for MOTS-C itself; Phase 1 safety data exists for a related analog (CB4211)
Regulatory status	Not approved anywhere for wellness/longevity use; named in Health Canada’s April 2026 advisory	Not approved anywhere; removed from FDA Category 2 in April 2026, not placed in Category 1, pending PCAC review
Typical protocol shape	Ongoing, frequency highly variable across community practice	Cycled — 8–12 weeks on, 4–8 weeks off
Signature experience	The flush — warmth/tingling within minutes of administration	Well tolerated; little beyond mild injection site reactions reported

Two Different Kinds of Molecule, Two Different Jobs

NAD+ isn’t a peptide at all — it’s a coenzyme, a small molecule every single cell depends on directly for energy production and DNA repair. It’s less a signal that tells cells to do something and more a resource cells need to do almost anything. That’s a fundamentally different role than a peptide plays.

MOTS-C is a peptide, but an unusual one — it’s the only compound in this entire guide series encoded in mitochondrial DNA rather than the nuclear genome. It’s released by mitochondria under metabolic stress and acts as a signal that recalibrates how cells handle energy, specifically by activating AMPK, a master energy-sensing enzyme.

The practical difference: NAD+ is a raw input to cellular energy machinery generally. MOTS-C is a specific signal that tells cells to shift their energy-handling behavior in a particular direction. Neither replaces the other, and there’s no real mechanistic overlap to speak of — they’re grouped in the same category because of what they’re used for, not because of how they work.

The Evidence Picture: Same Underlying Problem, Different Shape

Both compounds share a structural problem that’s worth naming directly: strong biological plausibility, real correlational human data, and essentially no completed injectable-intervention outcomes trials. But the specific shape of that evidence gap differs between them.

NAD+’s gap is unusually well-documented, because someone went looking for it directly. A rigorous, PRISMA-guided systematic review published in Ageing Research Reviews in 2025, covering literature from January 2010 through October 2025, explicitly searched for and found zero eligible outcomes trials for IV or IM NAD+ for any anti-aging or wellness indication. That’s a strong, direct, recent finding — not an absence of evidence inferred from silence, but a documented conclusion from a real search of the literature.

MOTS-C’s gap is more a matter of the compound simply being too new, compounded by a related-but-distinct analog complicating the picture. The compound most associated with human trial data — CB4211 — isn’t MOTS-C itself, but an analog developed by a separate company, which reached Phase 1 safety trials before that program appears to have stalled. There’s no equivalent systematic review specifically confirming an absence of MOTS-C outcomes trials the way NAD+ has, but the practical situation is similar: no completed efficacy trial exists for the compound as it’s actually researched and sold today.

Oral precursors complicate the NAD+ picture in a way MOTS-C doesn’t have an equivalent for. NAD+ has viable oral precursor alternatives (NMN, NR) with their own moderate, if mixed, human trial data — meaning there’s a real comparison to be made between routes for the same underlying goal. MOTS-C doesn’t have a comparably studied alternative delivery form; the injectable peptide is essentially the only research-accessible version.

Regulatory Status: A Genuine Difference in Category

NAD+ and MOTS-C aren’t regulated as the same type of thing, which matters more than it might seem.

MOTS-C is a peptide, and it moved through the same FDA compounding classification system as most other peptides in this guide series: placed into Category 2 in 2023, removed in April 2026 without being placed into Category 1, currently sitting in the same unclassified regulatory gap pending the Pharmacy Compounding Advisory Committee’s July 2026 review.

NAD+ isn’t a peptide, so it doesn’t move through that same specific classification framework in the same way — but it was still specifically named in Health Canada’s April 2026 advisory on unauthorized injectable products, grouped alongside peptides like BPC-157 and CJC-1295 despite the different molecular category, reflecting the advisory’s broader concern with unauthorized injectable products generally rather than a peptide-specific rule. NAD+’s regulatory story is also shaped by its wellness-clinic ubiquity in a way MOTS-C’s isn’t — NAD+ IV therapy is available at thousands of clinics globally, a scale of commercial availability that MOTS-C, as a newer and less mainstream compound, hasn’t reached.

Practical Differences Worth Knowing

Dosing frequency consensus differs sharply. MOTS-C has a fairly clear community standard (5mg, three times weekly, with structured cycling). NAD+ community practice is genuinely scattered — daily, several-times-weekly, and weekly protocols are all common, likely a direct reflection of the absence of trial data to anchor a standard.

The administration experience is genuinely different. NAD+’s flush is immediate, physically noticeable, and requires active management (slow administration, starting low) in a way MOTS-C’s administration simply doesn’t — MOTS-C is one of the better-tolerated, least eventful compounds in this entire guide series to actually inject.

Vial sizes and math differ substantially. NAD+ comes in much larger vials (commonly 500mg–1000mg) than MOTS-C (commonly 20mg–40mg), reflecting how much larger NAD+’s effective doses are in absolute terms.

Cycling philosophy differs. MOTS-C’s community-standard cycling (8–12 weeks on, 4–8 weeks off) reflects a specific mechanistic concern about diminishing AMPK-pathway returns with continuous activation. NAD+ is more commonly treated as an ongoing addition without a structured break, though there’s no strong evidence-based reason favoring either approach for either compound.

Which One Actually Fits Your Research Objective?

Choose NAD+ if: your interest is broad cellular energy metabolism and DNA repair capacity, and you’re comfortable with a compound whose evidence gap is thoroughly documented rather than simply under-explored — or if you’re specifically interested in comparing injectable use against the moderately-better-evidenced oral precursor alternatives.

Choose MOTS-C if: your interest is more specifically metabolic flexibility and exercise-linked outcomes, and you want a compound with a clearer, more consensus-driven community dosing structure, even though its human evidence base is younger and thinner than NAD+’s.

Consider both, mechanistically, if: you’re building a broader metabolic/longevity protocol — there’s no known conflict between the two, since they work through genuinely non-overlapping pathways (coenzyme substrate availability versus AMPK signaling). This is a reasonable inference from the mechanisms, not a claim backed by a trial demonstrating combined benefit.

Common Questions

Is either of these actually proven to slow aging in humans? No, not in a completed outcomes trial, for either compound, as things stand. Both rest on strong preclinical and mechanistic plausibility plus correlational human data (levels of both decline with age and in metabolic disease), not demonstrated human intervention outcomes.

Which has better real-world safety data? NAD+, simply by virtue of being older and far more widely used clinically since 1961, even though that early use was for an unrelated purpose (addiction treatment) and doesn’t constitute modern outcomes evidence. MOTS-C is a genuinely newer compound with a shorter track record of any kind.

Are these regulated the same way? No — MOTS-C moves through the FDA’s peptide-specific compounding classification system; NAD+ doesn’t, as a non-peptide coenzyme, though it was still named in Health Canada’s broader April 2026 advisory on unauthorized injectable products.

Is one more likely to become an approved drug first? Neither has a clear path to approval as things currently stand. MOTS-C’s most direct related clinical program (CB4211, a distinct analog) appears to have stalled after Phase 1. NAD+ has never been pursued as an approved drug in the way a novel peptide might be, given its status as a naturally occurring, unpatentable coenzyme.

Where to Go From Here

• NAD+: The Complete Guide
• MOTS-C: The Complete Guide
• Our Canadian Regulatory Landscape Guide
• Our Reconstitution and Storage Guide
• Our Certificate of Analysis and Vendor Verification Guide

---

This guide reflects the evidence and regulatory information available as of publication and will be updated periodically as new research emerges. It is provided for research and educational purposes only, does not constitute medical advice, and is not a substitute for consultation with a qualified healthcare professional. Aethon Labs does not intend for any compound discussed here to be used for human consumption.

AETHON LABS — Tested. Documented. Delivered.